Dictaphone signs $30 million contract with U.S. Army
Dictaphone signs $30 million contract with U.S. ArmyDictaphone, a subsidiary of Lernout & Hauspie, has signed a contract worth up to $30 million with the Army Medical Department. Under terms of the deal, L&H Dictaphone Healthcare
Dictaphone signs $30 million contract with U.S. Army
Dictaphone, a subsidiary of Lernout & Hauspie, has signed a contract worth up to $30 million with the Army Medical Department. Under terms of the deal, L&H Dictaphone Healthcare Solutions Group will provide dictation and transcription products and services to the armys medical facilities. Products covered by the contract include the companys enterprise voice, text, and continuous speech-recognition products. The goal is to provide the army with automated solutions for the creation, management, and analysis of patient medical records at up to 37 medical facilities worldwide.
- Search Again
- Return To HNN Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
